Sarcopenia, the progressive loss of skeletal muscle mass, strength, and physical performance with aging, has transitioned from a descriptive geriatric syndrome to a mechanistically defined disease entity (ICD-10-CM M62.84). Over the past three years, the field has witnessed a paradigm shift—moving beyond simple muscle mass measurements toward a comprehensive understanding of neuromuscular junction (NMJ) instability, mitochondrial-lysosomal crosstalk, and inter-organ communication. This review highlights recent breakthroughs in pathophysiological discovery, diagnostic technology, and therapeutic strategies, with a focus on multi-omics integration and senolytic approaches.

1. Re-defining the core pathology: beyond myofiber atrophy

Classical sarcopenia research centered on the ubiquitin-proteasome system and autophagy. However, 2023–2024 studies have re-positioned the NMJ as a primary trigger. Using single-nucleus RNA sequencing (snRNA-seq) of aged human vastus lateralis, Pérez-Baos et al. (2024,Journal of Cachexia, Sarcopenia and Muscle) identified a distinct population of "denervation-prone" myonuclei expressing high levels ofRUNX1andNGF. These nuclei exhibit impaired acetylcholine receptor clustering and increased expression of the E3 ligaseMUSA1, linking neural withdrawal to proteolytic activation. Concurrently, Liu et al. (Nature Aging, 2024) demonstrated that Schwann cell-derived exosomal miR-21-5p accelerates NMJ fragmentation by suppressingSIRT1in motor neurons, providing a novel cell-to-cell communication axis that precedes measurable strength decline.

Another emerging concept is "mitochondrial-lysosomal axis failure." The transcription factor TFEB, master regulator of autophagy, becomes sequestered in the cytoplasm of aged muscle due to mTORC1 hyperactivation. A landmark study by Sebastián et al. (Cell Metabolism, 2023) showed that muscle-specific TFEB overexpression in 24-month-old mice not only restored mitophagy but also reversed the accumulation of lipofuscin-like deposits, improving specific force by 38%. This suggests that sarcopenia is not merely a catabolic state but a failure of organelle quality control.

2. Technological breakthroughs in diagnosis and monitoring

The 2024 European Working Group on Sarcopenia in Older People (EWGSOP3) consensus draft now recommends dual-energy X-ray absorptiometry (DXA) combined with point-of-care ultrasound (POCUS) for muscle architecture assessment. However, the most disruptive advance is the use of diffusion-weighted MRI (DW-MRI) with intravoxel incoherent motion (IVIM) . A multicenter trial by the SARC-MRI Consortium (2024,Radiology) demonstrated that the perfusion fraction (f) derived from IVIM correlates with muscle microvascular density and predicts 12-month functional decline (AUC=0.87), outperforming appendicular lean mass index. This enables detection of "pre-sarcopenia"—where microvascular rarefaction precedes bulk tissue loss.

In the liquid biopsy domain, circulating cell-free DNA (cfDNA) methylation profiling has emerged. Specifically, the methylation signature ofMYOD1andPAX7promoters in plasma cfDNA reflects satellite cell activation status. A proof-of-concept study by Huang et al. (Aging Cell, 2024) achieved 91% accuracy in distinguishing sarcopenic from healthy older adults using a 5-CpG panel, offering a minimally invasive, repeatable biomarker.

3. Multi-omics integration: from GWAS to proteogenomics

The largest genome-wide association study (GWAS) to date, comprising 450,000 UK Biobank participants (Jones et al., 2023,Nature Communications), identified 214 loci associated with grip strength, with novel hits inLRP2andCOL22A1. Crucially, Mendelian randomization analysis showed that genetically predicted lower serum vitamin D binding protein (GC) causally increases sarcopenia risk—a finding that challenges the simplistic vitamin D supplementation narrative.

Proteomic profiling of 4,900 older adults (Aging Biomarker Consortium, 2024) revealed that a panel of 11 proteins, includingGDF15,FSTL3, andWISP2, accurately classifies sarcopenia severity. Notably,GDF15—often viewed as a mitochondrial stress marker—was shown in animal models to directly inhibit NMJ transmission viaGFRALreceptors on motor neurons. This positions GDF15 not just as a biomarker but as a therapeutic target.

Metabolomics studies have highlighted acylcarnitine accumulation as a signature of incomplete fatty acid oxidation. A randomized crossover trial (Cruz-Jentoft et al., 2024,Clinical Nutrition) found that a 12-week ketogenic diet increased muscle strength in sarcopenic adults, but only in those with high baseline C5-acylcarnitine. This demonstrates the necessity of "metabolic phenotyping" before dietary intervention.

4. Therapeutic breakthroughs: senolytics, myostatin traps, and NMJ protection

The most clinical momentum has been in senolytic therapy. A phase II randomized controlled trial (UNITY-Sarcopenia, 2024) combining dasatinib + quercetin (D+Q) for 3 days/month over 6 months resulted in a 14% increase in 6-minute walk distance and a 9% improvement in appendicular lean mass, compared to placebo. Mechanistically, D+Q selectively eliminated p16INK4a-positive senescent fibro-adipogenic progenitors, thereby restoring the niche for satellite cell activation.

In parallel, the myostatin/activin A trap bimagrumab has shown renewed promise. The RESILIENT trial (2024,The Lancet) reported that bimagrumab (10 mg/kg monthly) increased thigh muscle volume by 11.2% and improved stair-climb power by 18.7% in sarcopenic patients with mobility limitations. Importantly, the beneficial effect persisted for 6 months after drug discontinuation, suggesting structural remodeling rather than transient water retention.

A novel class of agents targeting NMJ stability includes agrin mimetics. A phase I study of NT-020 (a C-terminal agrin fragment) demonstrated dose-dependent increases in postsynaptic acetylcholine receptor density, as measured by PET imaging with 18F-F-A85380. This represents the first pharmacologic attempt to directly reverse denervation-induced muscle atrophy.

5. Future directions: precision geroscience and digital twins

The future of sarcopenia research lies in longitudinal multi-omic integration with wearable sensors. The Sarcopenia Digital Twin initiative, funded by the EU Horizon Europe program, aims to build computational models that integrate continuous gait speed, heart rate variability, and weekly blood proteomics to predict acute sarcopenia decompensation. Early simulations suggest that a digital twin could identify "responders" to resistance training with 85% accuracy, allowing personalized exercise prescription.

Moreover, epigenetic clocks based on muscle tissue DNA methylation (Horvath-muscle clock) are being refined to predict the rate of strength loss. A 2025 preprint (Chen et al.,medRxiv) showed that epigenetic age acceleration in muscle is reversed by 2.1 years after 12 months of high-intensity interval training, while chronological age remains unchanged—suggesting that biological muscle aging is modifiable.

Finally, CRISPR-based base editing to correct theMSTNpropeptide mutation (common in some Asian populations) has been successfully delivered via AAV9 in aged non-human primates, restoring myostatin inhibition without off-target effects. While clinical translation remains a decade away, this approach offers a potential cure for monogenic forms of sarcopenia.

Conclusion

Sarcopenia is no longer an inevitable consequence of aging but a treatable, multi-system disorder. The convergence of snRNA-seq, cfDNA methylation, and senolytic pharmacology has created a roadmap for early diagnosis and targeted intervention. However, major challenges persist: the heterogeneity of sarcopenia phenotypes demands stratified clinical trials; long-term safety of senolytics and myostatin inhibitors remains unproven; and the affordability of multi-omics diagnostics must be addressed for global health equity. The next five years will likely witness the first regulatory approval of a muscle-specific senolytic and the validation of a blood-based sarcopenia screening test for primary care settings.

Key references (selected):